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Abstract The systematic isolation of circulating regulatory pep- 
tides which generate cGMP as second messenger resulted in the 
identification of a novel member of the gnanylin family. In the 
present study we describe the purification and amino acid se- 
quence of a new guanylate cyclase C activating peptide (GCAP- 
II). GCAP-II contains 24 amino acids in the following sequence: 
FKTLRTIANDDCELCVNVACTGCL. Its molecular mass is 
2597.7 Da. The 16 C-terminal amino acids are identical to 
uroguanylin from human urine. Native and synthetic GCAP-II 
activate GC-C, the specific gnanylate cyclase receptor, of cul- 
tured human colon carcinoma (T84) cells. GCAP-II stimulates 
chloride secretion in isolated human intestinal mucosa mediated 
by intracellular cGMP increase. GCAP-II specific antibodies 
were used to localize the peptide by immunohistochemistry in 
entero-endocrine cells of the colonic mucosa. 
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intestinal tissues, such as kidney, liver, reproductive tract, adre- 
nals, airway epithelia, and pancreas [4,5]. In addition, a larger 
molecular form of this peptide, namely guanylin-22-115, circu- 
lates as a bioactive peptide in human blood, suggesting that this 
peptide regulates the function of different arget organs by an 
endocrine interaction [8]. 
Uroguanylin, a second ligand of the GC-C receptor, has been 
recently purified from human and opossum urine [9,10]. The 
structural homology and the similar biological activity of gua- 
nylin and uroguanylin suggest hat they are members of a 
peptide family, the main function of which is the activation of 
GC-C in the intestine and in other tissues. With regard to 
putative ndocrine interactions of this system we initiated a 
systematic search for further endogenous activators of GC-C 
circulating in human blood. Here we report the isolation, the 
biochemical and functional characterization, and the immu- 
nohistochemical localization of a new GCAP related to 
uroguanylin. 
1. Introduction 
The second messenger cGMP constitutes an important sig- 
nalling system. Among the cellular functions regulated through 
this pathway is the electrolyte transport of various epithelia. In 
the intestinal epithelium this system is coupled to a particulate 
guanylate cyclase (GC-C) which is abundantly ocalized in the 
apical membrane of the enterocytes [1]. Intestinal GC-C is 
activated by heat-stable enterotoxins (ST) which are small pep- 
tides secreted by several pathogenic bacteria [1]. Subsequent 
increases in epithelial cGMP mediate the activation of cystic 
fibrosis transmembrane conductance r gulator (CFTR) in the 
apical membrane which in turn results in chloride and water 
secretion and secretory diarrhea [2]. Recently, guanylin, the 
first endogenous ligand to this GC-C receptor was discovered 
by Currie and coworkers [3]. Northern blot and immunohisto- 
chemical analysis have revealed that guanylin occurs in the 
mucosa of the mammalian i testine (see reviews [4] and [5]). 
The peptide is probably released from entero-endocrine cells 
[6,7] into the intestinal lumen to activate the GC-C and conse- 
quently the chloride transport in enterocytes by means of a 
paracrine interaction [5]. However, several data indicate that 
the guanylin/GC-C system is not exclusively confined to the 
intestine. Low levels of GC-C have been detected in extra- 
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2. Materials and methods 
2.1. T84 cell cGMP bioassay 
The bioassay for the detection of GC-C activating peptides was 
carried out as described indetail [3,8]. Human colon carcinoma (T84) 
cells were used at passages 3445. The cells were incubated for 60 rain 
with aliquots derived from the chromatographic fractions, in the pres- 
ence of the phosphodiesterase inhibitor isobutylmethylxanthine 
(IBMX, 1 raM; Sigma, Deisenhofen, Germany). The effects on intracel- 
lular cGMP content were compared with those of synthetic human 
guanylin (IPF, Hannover, Germany)and E. coli heat-stable enterotoxin 
(STa; Sigma, Deisenhofen, Germany). cGMP concentrations were 
measured using a specific radioimmunoassay [11]. 
2.2. Purification of GCAP-H 
Hemofiltrate (HF) from patients with chronic renal insufficiency was 
obtained at a local nephrology center (Nieders/ichsisches Z ntrum ftir 
Nephrologie, Hannoversch-Miinden, Germany). Freshly collected HF 
was immediately acidified with hydrochloric acid (HC1) to pH 3.0 and 
cooled to 4°C. Batches of 750 liters were diluted 1 : 3 (v/v) with deion- 
ized water and applied to a cation-exchange column (Fractogel TSK 
SP 650 (M), Merck, Darmstadt, Germany). The peptides bound to the 
column were eluted with 0.5 M ammonium acetate and the eluate was 
lyophilized. Peptide xtracts of batches of 3000 liters of HF were resus- 
pended in deionized water and subjected toan ultrafiltration using a 
membrane with a cut-off of 20 kDa (cellulose triacetate membrane; 
Sartorius, GSttingen, Germany) to eliminate most of the remaining 
plasma proteins uch as albumin. The filtrate was then acidified with 
HC1 (pH 3.0) and subjected toseven subsequent chromatographic pu-
rification steps. After each step, aliquots of the fractions were assayed 
for cGMP generation i T84 cells, and the active fractions were pooled 
for further purification. 
Step l: Preparative r versed phase (RP) C18 chromatography (300 
A, 15 20 um, 47 x 300 mm; Vydac, Hesperia, CA, USA). The peptides 
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were eluted with a flow rate of 40 ml/min and fractionated with the 
following radient: 10 to 60% eluent B in 30 min (eluent A: 0.01 N HC1; 
eluent B: 80% acetonitrile, 0.01 N HC1). 
Step 2: RP C18 (300 A, 15-20 ¢tm, 47 x 300 ram; Vydac, Hesperia, 
CA, USA); gradient from 32 to 48% eluent B in 42.5 min (eluent A: 0.01 
N HCI; eluent B: 80% acetonitrile, 0.01 N HC1); flow rate, 40 ml/min. 
Step 3:.Strong cation-exchanger (300/~, 5/tin, 10 x 50 mm; Pepkat, 
Biotek, Ostringen, Germany); gradient from eluent A (25 mM 
Na2HPO4, pH 3.0) to 40% eluent B (1.5 M NaC1, 25 mM NazHPO4, 
pH 3.0) in 60 min and to 100% eluent B in 5 rain; flow rate, 3 ml/min. 
Step 4: RP C4 (300 A, 5/lm, 4 x 250 ram; ProRP, Biotek, Ostringen, 
Germany); gradient from 25 to 45% eluent B in 60 min (eluent A: 0.1% 
trifluoroacetic a id (TFA), eluent B: 80% acetonitrile, 0.1% TFA); flow 
rate, 0,7 ml/min. 
Step 5, 6 and 7: The last three steps were carried out with the same 
RP C18 column (300 A, 5 ¢tm, 4.6 x 250 mm; Vydac, Hesperia, CA, 
USA). The peptides were eluted at a flow rate of 0.7 ml/min using as 
eluent A 0.01 N HC1 and as eluent B 80% acetonitrile, 0.01 N HCI. The 
gradient was 25 to 45% eluent B in 60 min (step 5), 25 to 45% eluent 
B in 80 rain (step 6) and 28 to 45% eluent B in 51 rain (step 7). 
2.3. Sequence analysis 
The amino acid sequence of the purified peptide was determined by 
Edman degradation using an ABI 473A gas-phase sequencer with 
standard program and gradient (Applied Biosystems, Weiterstadt, Ger- 
many). 50 to 100 pmol of the purified bioactive peptide were applied 
onto the Bioprene-coated glass fibre disc (Applied Biosystems, Weiter- 
stadt, Germany). 
2.4. Mass spectrometry (MS) 
The molecular weight of the purified peptide was determined by 
microbore-HPLC-MS coupling using the dual syringe solvent delivery 
system ABI 140A (Applied Biosystems, Weiterstadt, Germany) with an 
AQS 1.0 x 250 mm RP C18 column (YMC, Schernbeck, Germany) and 
the API 111 biomolecular mass analyser (Sciex, Perkin Elmer, Langen, 
Germany) equipped with articulated ion spray inlet. Single scans from 
400 to 2400 atomic mass units were recorded every 7 s during separation 
time. The column outlet was directly transferred to the electrospray 
unit. Molecular masses were determined in positive ion mode. 
2.5. Peptide synthesis" 
Peptide synthesis was carried out on a 9050 peptide synthesizer using 
a preloaded Fmoc-L-Leu-PEG-PS resin (PerSeptive/Biosearch, 
Freiburg, Germany) as described [12]. Disulfide bridges were intro- 
duced selectively using Fmoc-L-Cys(Trt)-OH and Fmoc-L-Cys(Acm)- 
OH with subsequent air and iodine oxidation procedures. Purity and 
identity of the bicyclic peptide were checked by HPLC, capillary zone 
electrophoresis (Biofocus 3000, Bio-Rad, Mfinchen, Germany), and 
electrospray mass spectrometry (Sciex API III, Perkin Elmer, Langen, 
Germany). 
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Fig. 1. Final purification of GCAP-II by RP C18 chromatography. 
HPLC conditions are given in section 2. B: eluent B (%, v/v). Shaded 
columns indicate the bioactivity. On the right side of the graph, concen- 
tration-dependent ac ivation ofT84 cGMP by enterotoxin (STa: 10 pM 
to 10 nM). 
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Fig. 2. Electrospray mass spectrum of the purified peptide GCAP-II. 
Mass was calculated from the multiple charge ions [M + 2H] 2÷ and 
[M+3H] 3.. 
2.6. Ussing chamber experiments 
Specimens of jejunum were obtained from patients undergoing ab- 
dominal surgery at Hannover Medical School. The use of tissue was 
approved by the Human Ethics Committee of Hannover Medical 
School. The clinical conditions requiring removal of intestine were 
carcinomas of the gut or pancreas. Tissues used for experimental stud- 
ies were taken from macroscopically normal areas distant from the 
pathologically affected tissue. After dissection of muscle layers, sheets 
of isolated mucosa were mounted in Ussing chambers and automati- 
cally voltage-clamped as described previously [13]. Short-circuit current 
(Isc) was continuously recorded. The transepithelial conductance was 
determined each minute by bipolar voltage pulses of 1 inV. After an 
equilibrium period of 30 min cumulative concentrations of synthetic 
peptide were added to the mucosal reservoir. 
2. 7 Immunohistochemistry 
A multiple antigenic peptide (MAP) consisting of a branched hep- 
talysine core with eight copies of the N-terminal domain of GCAP-II 
(FKTLRTIANDD) covalently bound was synthesized [12,14]. Antisera 
were raised in rabbits and used to localize the peptide in various tissues 
such as colon, liver, kidney, and stomach. Controls were carried out as 
routinely [6], for preabsorption tests the entire synthetic GCAP-II as 
well as the MAP and the linear undecapeptide w re used in excess. 
3. Results  
In initial experiments, the peptide fractions from human he- 
mofiltrate separated via RP-HPLC were assayed for the in- 
crease of cGMP in T84 cells. Two major GC-C stimulating 
activities eluted from the RP C18 column (data not shown). 
Isolation of the second activity led to the purification of the 
high molecular weight guanylin (guanylin-22 115) [8]. To char- 
acterize the first activity, 3000 liters HF were used to purify the 
corresponding bioactive peptide to homogeneity by a series of 
subsequent HPLC fractionations. After six chromatographic 
purification steps, three bioactive fractions were obtained. Re- 
chromatography of the fraction showing the strongest bioactiv- 
ity, a single peak was detected, revealing that the corresponding 
fraction consisted of purified material (Fig. 1). Electrospray 
mass spectrometric analysis showed that the molecular weight 
of the corresponding peptide is 2597.7 Da (Fig. 2). 
Sequence analysis of the purified peptide using Edman degra- 
dation resulted in the following sequence: FKTLRT IANDD-  
XELXVNVAXTGXL.  Comparison of the sequence of this sec- 
ond circulating uanylate cyclase C activating peptide (GCAP- 
II) with other proteins in the SwissProt and EMBL databases 
showed that the sequence is new and that the 16 amino acids 
from position 9 to position 24 of GCAP-I I  are identical to those 
36 R. Hess et al./FEBS Letters 374 (1995) 34-38 
of human uroguanylin, the peptide isolated from urine by Kita 
and coworkers [10] (see Fig. 3). The molecular weight deter- 
mined by MS corresponds to the theoretical molecular weight 
calculated from the sequence supposed that the non-detectable 
amino acids (X) are cysteines and that two disulfide bonds are 
formed. Thus, GCAP-II represents an N-terminally extended 
form of uroguanylin. In addition to the structural similarity 
with guanylin, acorresponding biological activity was revealed. 
The striking characteristics of these peptides include the four 
conserved cysteine residues (for comparison, see Fig. 3) and the 
fact that they both circulate as bioactive peptides in human 
blood. 
The other two bioactive fractions of chromatographic step 
6 were separately subjected to HPLC-MS coupling. The main 
constituent of both was the 2597.7 Da peptide, indicating that 
GCAP-II was also responsible for the bioactivity of these frac- 
tions. 
The disulfide bridges of the chemically synthesized GCAP-II 
were linked between the cysteines in positions 12-20 and 15-23, 
as previously suggested for guanylin or uroguanylin (Fig. 3). 
The biological activity of synthetic GCAP-II was assessed by 
evaluating its effects on T84 cell cGMP content as well as on 
electrolyte transport in isolated human intestinal mucosa. Syn- 
thetic GCAP-II causes a concentration-dependent increase in 
cGMP levels in T84 cells, with a threshold concentration of 10 
nM. Its effective concentration range appears o far similar to 
that of synthetic human guanylin (guanylin-101 15) (Fig. 4). 
The effect of GCAP-II on intestinal electrolyte transport was 
analyzed by Ussing chamber experiments with isolated mucosal 
strips of human jejunum using synthetic GCAP-II. Addition of 
GCAP-II to the luminal compartment induces a concentration- 
dependent increase in Isc, again with a threshold concentration 
of 10 nM (Fig. 5A). This effect is very similar to that of human 
guanylin, when tested in parallel chambers (Fig. 5B). The Isc 
increases are in the same order of magnitude as the rise in 
cGMP in the T84 cell assay. The maximal Isc increases evoked 
by GCAP-II or guanylin (1 /.tM) are rapidly and completely 
reversed by the subsequent addition of 0.1 mM bumetanide, an 
inhibitor of the basolateral Na+-K+-2CI - cotransporter, to the 
serosal solution. This indicates that both peptides timulate 
electrogenic chloride secretion in human intestine. 
The immunohistochemical analysis of the colonic mucosa 
revealed that GCAP-II immunoreactivity is localized exclu- 
sively in entero-endocrine cells (Fig. 6). Other cells in the epi- 
thelium or in the lamina propria or in the other organs investi- 
gated are devoid of immunoreactivity for GCAP-II. 
4. Discussion 
The present study describes the isolation and the sequence 
analysis of a second GC-C-activating peptide circulating in 
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Fig. 3. Comparison of the amino acid sequences ofhuman GCAP-II, 
human uroguanylin, human guanylin-101 15 and E. cob heat-stable 
enterotoxin (STa). Identical amino acids are boxed. Human GCAP-II 
represents he NHz-terminal extended form of human uroguanylin. 
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Fig. 4. Effects of activators of GC-C on intracellular cGMP levels in 
T84 cells. Cells were incubates with the indicated concentrations for 60 
min in the presence of 1 mM IBMX. Values represent means + S.D. 
(n = 4) 
human blood plasma: GCAP-II. It contains 24 amino acids and 
represents an N-terminally extended form of uroguanylin, the 
16-amino acid peptide recently isolated from urine [10]. As a 
source for human plasma peptides we used hemofiltrate col- 
lected from patients with renal insufficiency, in analogy to our 
previous tudy demonstrating the molecular form of circulating 
guanylin [8]. Native GCAP-II induced marked increases in 
cGMP content ofT84 cells, indicating that the circulating pep- 
tide is an active hormone and not merely a precursor form. This 
conclusion is confirmed using synthetic GCAP-II, that stimu- 
lates dose-dependent cGMP formation in T84 cells as well as 
chloride secretion from the isolated human intestinal mucosa. 
In both experimental models the effects of GCAP-II are com- 
parable to those of synthetic human guanylin, suggesting simi- 
lar affinities of both peptides for their common intestinal recep- 
tor, GC-C. In contrast, synthetic uroguanylin was somewhat 
more potent han guanylin in the stimulation of GC-C activity 
0.1 mM bumetanide 
A 
t t t 
0.1 nM 1 nM 10nM 0.1 mM bumetanide 
B 
t , ~tM 
°. 
2 min 
Fig. 5. Original tracing of an Ussing chamber experiment with isolated 
human jejunal mucosa. Cumulative addition of synthetic GCAP-II (A) 
and synthetic human guanylin-101-115 (B) to the luminal solution 
induced concentration-dependent increases in Isc. The increase in Isc 
was rapidly reversed by the subsequent addition of 0.1 mM bumetanide 
to the serosal solution. 
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Fig. 6. Immunohistochemical demonstration fGCAP-II immunoreac- 
tivity in human colonic mucosa. Note the staining in a granulated cell 
type of the columnar epithelium characteristic for entero-endocrine 
cells, x 500. 
in T84 cells [9,10]. Possible xplanations for this discrepancy are 
passage-related differences in the responsiveness of T84 cells, 
the different incubation times used for experimentation (60 min 
in our study and 30 rain in the study of Kita and coworkers [10]) 
and differences in the receptor affinity of GCAP-II  and the 
shorter uroguanylin. 
Recently, the uroguanylin cDNA has been cloned [15]. From 
the cDNA the sequence of a 112 amino acid prohormone can 
be predicted. The sequence of GCAP-II  is contained in the 
C-terminal region from positions 89 to 112 of the precursor. 
Future studies will reveal whether uroguanylin, the 16-amino 
acid peptide xcreted in urine, derives from an alternative proc- 
essing of the precursor, or whether it constitutes an in vivo 
degradation product of circulating GCAP-II. 
The tissue sites of guanylin production have been examined 
by Northern blot analysis and immunohistochemistry: both 
methods indicate that this peptide is produced mainly in the 
intestine and, at lower levels, in pancreas, adrenals, kidney, 
lung and uterus (see reviews [4,5]). The exact issue distribution 
of GCAP-II  or uroguanylin is not established. Northern blot 
analysis using total RNA showed a very high expression of the 
GCAP-II-gene in human colon [15]. With regard to the high 
levels of uroguanylin in urine it has been postulated that the 
kidney may be the main source of this peptide [10]. However, 
our attempts to demonstrate a significant gene expression in 
extraintestinal tissues, even in kidney, were unsuccessful. In the 
colon, GCAP-II may be released luminally, to reach the recep- 
tor (GC-C) in the brush-border membrane of the enterocytes 
(paracrine secretion). Also basolateral release may occur to 
contribute to circulating GCAP-II. 
As we have already postulated for circulating uanylin [8], 
GCAP-H may serve as an endocrine link between the intestine 
and distant issues involved in the regulation of fluid and elec- 
trolyte homeostasis, In particular, several experimental obser- 
vations uggest that the kidney may be a main target issue for 
circulating GCAP-II. White and coworkers [16] showed that 
renal tissue contains a functional receptor for the E. coli heat- 
stable enterotoxin (STa). Natriuretic effects of STa have been 
demonstrated both in vivo, in anaesthetized animals, and in 
vitro, in isolated perfused rat kidneys, in association with large 
increases in urine levels of cGMP [17,18], Regarding the high 
urine levels of uroguanylin it is probable that circulating 
GCAP-II  is filtered into the renal tubules. The effect may be 
mediated like the natriuresis induced by STa, either directly or 
after local cleavage forming the shorter uroguanylin. Northern 
analysis of GC-C and binding studies with [125I]STa indicated 
the localization of the receptor in other extraintestinal tissues 
such as liver, reproductive tract, airways, and pancreas [4]. 
Thus, the circulating ligands guanylin-22 115 and GCAP-II 
may form part of an endocrine pathway for the regulation of 
multiple physiological processes. 
In summary, the present study describes the isolation and the 
chemical and functional characterization f a second GC-C 
stimulating peptide (GCAP-II) from human hemofiltrate. 
GCAP-II  represents an N-terminally extended form of 
uroguanylin and belongs to the guanylin/STa peptide family. 
Future studies will focus on the endocrine role of this circulat- 
ing peptide family that might constitute a novel communication 
system between the intestine and extraintestinal tissues. 
Acknowledgements: The authors wish to thank Mrs Ilka Uhrlandt for 
her excellent technical assistance. We are indebted to J. Klempnauer 
and J. J/ihne (Department of Gastrointestinal Surgery, Hannover Med- 
ical School) who provided specimens for the Ussing chamber experi- 
ments. This work was supported by Deutsche Forschungsgemeinschaft 
(DFG Ku 1037/1-1). 
References 
[1] Field, M., Graf, L.H., Larid, W.J. and Smith, EL. (1978) Proc. 
Natl. Acad. Sci. USA 75, 2800 2804, 
[2] Chao, A.C., de Sauvage, F.J,, Dong, Y.J., Wagner, J.A., Goeddek 
D.V. and Gardner, P. (1994) EMBO J. 13, 1065-1072. 
[3] Currie, M.G., Fok, K.F., Kato, J., Moore, R.J., Hamra, F.K., 
Duffin, K.L. and Smith, C.E. (1992) Proc. Natl. Acad. Sci. USA 
89, 94%951. 
[4] Forte, L.R. and Currie, M.G. (1995) FASEB J. 9, 643-650. 
[5] Forssmann, W.G., Cetin, Y., Hill, O., M/igert, H.J., Kuhn, M., 
Kulaksiz, H. and Rechkemmer, G. (1995). In: Gastrointestinal 
Tract and Endocrine System (M.V. Singer ed.), pp. 279 292, 
Kluwer Academic Publishers, London. 
[6] Cetin, Y., Kuhn, M., Kulaksiz, H., Adermann, K., Bargsten, G., 
Grube, D. and Forssmann, W.G. (1994) Proc. Natl. Acad. Sci. 
USA 91, 2935 2939. 
[7] Hill, O., Kuhn, M., Zucht, H. D., Cetin, Y., Kulaksiz, H., Ader- 
mann, K., Klock, G., Rechkemmer, G., Forssmann, W.G. and 
M~igert, H.J. (1995) Proc. Natl, Acad. Sci. USA 92, 2046 
2050. 
[8] Kuhn, M., Raida, M., Adermann, K., Schulz Knappe, P., Gerzer, 
R., Helm, J.M. and Forssmann, W.G. (1993) FEBS Lett. 318, 
205-209. 
[9] Hamra, F.K., Forte, L.R., Eber, S.L., Pidhorodeckyj, N.V., 
Krause, W.J., Freeman, R.H., Chin, D.T., Tompkins, J.A., Fok, 
K.F., Smith, C.E., Duffin, K.L., Siegel, N.R. and Currie, M.G. 
(1993) Proc. Natl. Acad. Sci. USA 90, 10464~10468. 
[10] Kita, T., Smith, C.E., Fok, K.F., Duffin, K.L., Moore, W.M., 
Karabatsos, P.J., Kachur, J.F., Hamra, F.K., Pidhorodeckyj, 
N.V., Forte, L.R. and Currie, M.G. (1994) Am. J. Physiol. 266, 
F342 F348. 
[11] Kaever, V. and Resch, K. (1985) Biochim. Biophys. Acta 846, 
216-225. 
38 R. Hess et al./FEBS Letters 374 (1995) 34-38 
[12] Adermann, K., ¥ilja, E, Kuhn, M., Austermann, S. and Forss- 
mann, W.G. (1994) In: Innovation and Perspectives inSolid Phase 
Synthesis (R. Epton ed.), pp. 429432, Mayflower Worldwide, 
Birmingham, UK. 
[13] Kuhn, M., Adermann, K., Jahne, J., Forssmann, W.G. and Rech- 
kemmer, G. (1994) J. Physiol. 479, 433~40. 
[14] Tam, J.E (1988) Proc. Natl. Acad. Sci. USA 85, 5409-5413. 
[15] Hill, O., Cetin, Y., Cieslak, A., M/igert, H.J. and Forssmann, 
W.G. (1995) submitted. 
[16] White, A.A., Krause, W.J., Turner, J.T. and Forte, L.R. (1989) 
Biochem. Biophys. Res. Commun. 159, 363-367. 
[17] Lima, A.A.M., Monteiro, H.S.A. and Fonteles, M.C. (1992) Phar- 
macol. Toxicol. 70, 163-167. 
[18] Freeman, R.H., Forte, L.R., Hamra, F.K., Currie, M.G. and 
Krause, W.J. (1994) FASEB J. 8, A552 (abstr.). 
